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Behc ¸et disease is a chronic relapsing vasculitis with unclear etiology and immunopathogenesis. Antigenic stimuli, antigen
presenting cells, T cells, monocyte, and neutrophil and endothelial cells are major parts of the pathology of the disease.
Understanding of the new pathogenic mechanisms based on molecular structure of the disease helps us in improving the novel
therapeutic modalities. These drugs target speciﬁc and nonspeciﬁc inhibition of the immun system. These therapies include
biologic agents, new topical and systemic immunosuppressants, tolerizing agents, and immunoablation. Novel treatment will be
promising to treat the especially recalcitrant cases to conventional therapy. In this paper, new aspect of the immunopathogenesis
of Behc ¸et’s diseases and novel treatment modalities will be discussed.
1.Introduction
Behc ¸et disease (BD) is a vasculitis that, characterized by
recurrent aphthous stomatitis, genital ulcers, skin lesions,
relapsing uveitis, articular, neurologic, urogenital, vascular,
intestinal,andpulmonarymanifestations[1–3].BDhasbeen
reported worldwide but has a distinct geographic distrubi-
tion, with highest prevalences in countries such as Turkey,
˙ Iran, and Japan which are place on silk road. Although much
has been learned during recent years on the pathogenesis
and treatment of the disease, the etiology and pathogenesis
of BD have not been fully clariﬁed [4, 5]. Symptoms of the
diseaseareconsideredtobebasedonthecorrelationbetween
the genetic intrinsic factors and the triggering extrinsic
factors,becausemorethan60% ofBDpatients areassociated
withHLA-B51.Immune-mediatedmechanismsplayamajor
role in the pathogenesis of the disease, and inﬂammatory
mediators are also involved [4–6]. Nowadays, recent investi-
gations have made clear explanations about the pathogenesis
of the disease. The hypersensitivity of T lymphocytes to
diﬀerent types of antigens plays a crucial role in the
pathogenesis [3–6].
The present paper overviews an update on the immun-
opathogenesis of BD and also novel treatment based on
pathogenesis.
2. Immunopathogenesis of Behc ¸et’sDisease
BD is an inﬂammatory disorder characterized mainly by
mucocutaneous ﬁndings and uveitis. However, it can be
present with other cutaneous symptoms such as pseudofolli-
culitis, erythema nodosum, and pyoderma gangrenosum [2–
5]. It can be present with articular, neurological, pulmonary,
intestinal manifestations other than classical triad. The close
relationship between the genetic and triggering external fac-
tors is thought to be present in the pathogenesis of BD [3,
4]. The immunopathogenesis of BD is shown in Figure 1.
CriticalregionforBDinthehumanmajorhistocompatibility
complex (MHC) gene could be pinpointed to a 46 kb seg-
ment between the MHC class I gene and HLA-B51 gene [5].
2.1. Heat Shock Proteins (HSP). HSP, which essentially
scavenge denatured intracellular proteins, are supposed to be
























Figure 1: The immunopathogenesis of Behc ¸et’s diseases.
a variety of stressful conditions, and they may be involved
in the pathogenesis of some autoimmune diseases [5]. The
serum levels of IgA antibodies to mycobacterial Hsp-65,
which cross recats with selected strains of S. Sanguinis,a r e
increased signiﬁcantly. These HSP presented by APCs can
directly stimulate α, beta T cells, and γδ+T cells which play
important roles in the oral mucosal immunity as the ﬁrst
defense against microorganisms. Altered expression of Hsp-
60 was found in ulcerative lesions of BD and RAS suggesting
that HSP-60 has an association with the etiology or chronic-
ity of these inﬂammatory lesions [7].
2.2. APCs (Antigen Presenting Cells). APC is specialized cell
that helps ﬁght oﬀ foreign substances that enter the body.
Diﬀerent types of antigens include viruses, bacteria, heat
shock protein, and endothelial antigens that stimulate the
APC. These cells send out signals to T cells (other immune
system cells) when an antigen enters the body [6]. Antigen
presentation stimulates T cells to become either “cytotoxic”
CD8+ cells or “helper” CD4+ cells. Cytotoxic cells directly
attack other cells carrying certain foreign or abnormal
molecules on their surfaces. Helper T cells, or Th cells,
coordinate immune responses by communicating with other
cells. Dysfunction of the APC is responsible for T-cell hyper-
sensitivity. And also this reaction expresses delayed type
hypersensitivity mediated by interleukins such as IL-12 and
IL-18 in the cutaneous lesions [4].
2.3. Neutrophils. These cells are the main elements of the
innate immunity. Meanwhile, cytokines and chemokines se-
creted from APCs and T cells induce the neutrophil hyperac-
tivation. Hyperactivity of the neutrophils is a major part of
the immunological abnormalities observed in BD [5, 6, 8].
Activated neutrophils secrete some cytokines which prime
themselves and also stimulate Th1 cells. Th1 lymphocytes
have a major role in immunopathogenesis of BD [6, 8].
2.4. γδ+T Cells. γδ+T cells, which are important of mucosal
immunity have an crucial role. Activity of the BD increases
with high level of γδ+T cells in circulation and mucosal
lesions. CD+8 γδ+T cells rather than CD4+ T cells were
activated in vivo in Behc ¸et’s patients [3, 6, 8]. In our study,
expression of the γδ+ Tc e l l si no r a lu l c e r sf r o mB Dp a t i e n t s
were studied. It was found heterogeneous expression of the
γδ+T cells throughout the epithelium and in connective
tissue around the ulcer base [9].
2.5. Proinﬂammatory Cytokines. It was claimed that tumor
necrosis factor (TNF) α gene is closely linked to the HLA-
B 51 gene, in view of the major role played by this proin-
ﬂammatory cytokine in BD [3, 6, 8]. An overproduction of
proinﬂammatory cytokines from cellular resources appears
to be responsible for the inﬂammatory reaction in BD, with
interferon-γ,T N F - α, IL-6, IL-8, and IL-12 being higher
in patients with BD. T-cell-produced cytokines, includingPathology Research International 3
interleukin(IL)-2,tumornecrosisfactor(TNF)-α,interferon
(IFN)-γ, IL-12 and IL-18, are elevated and probably con-
tribute to neutrophil and endothelial cell activation. And
also IL-12, and IL-18, which are mainly produced by APCs,
regulatetheneutrophilfunctionandmayplayimportantrole
in the skewing of immune response [4, 8].
2.6. Th17 Cells. It was reported a marked increase in Th17
cellnumbers and a decreased frequency of CD4 (+) forkhead
box protein 3 positive Treg cells in the peripheral blood of
patients with active BD [8–12]. Th17/Th1 ratio was elevated
in BD patients with uveitis or folliculitis compared to
those without it [11]. Th17 cells regulate inﬂammation via
productionofdistinctcytokinessuchasIL-17.Thereisgrow-
ing evidence that Th17 cells are pathological in many human
autoimmune and inﬂammatory diseases [8–12]. Th17 cells
r e p r e s e n tan e ws u b s e to fT hc e l l s ,w h i c hm a i n l yp r o d u c e
IL-17A-F, IL-22, and TNF-α. IL-6 and TGF-ß induce the
diﬀerentiation of Th17 cells form naive T cells. Hamzoui et
al. found high level of TBX 21 (Th1), RORC (Th17) and
Foxp3 (Treg) in neuro-BD. They postulated Th1 and Th17
mRNA expressions involving a possible impairment of Treg
cells [13].
2.7. IL-21. Geri et al. demonstrated the presence of the
IL-21 and IL 17-A producing T cells within the cerebro-
spinal ﬂuid, brain parenchyma inﬂammatory inﬁltrates, and
intracerebral blood vessels form patients with active BD
and central nervous system involvement. The stimulation of
CD(+) T cells with IL-21 increased Th17 and Th1 diﬀeren-
tiation and decreased the frequency of Treg cells. IL-21 re-
presents a promising target for novel therapy in BD [14].
Jiang et al. found strong association of a single-nucleotide
polymorphism of IL-23R with BD. The results suggested that
IL-23R is predisposing genotypes for BD [15].
2.8. VEGF. In other study, VEGF (vascular endothelial
growth factor) was measured in the cerebrospinal ﬂuid in
neuro-BD and was found signiﬁcantly increased. They spec-
ulated that VEGF may be associated with the increased
percentages of CD4 cell subpopulation [16].
2.9. Vitamin D. Serum vitamin D concentrations and BD
activity were investigated. Active BD was associated with
lower serum vitamin D levels. These results showed that low
levels of vitamin D were associated with a decrease in Treg
cellsandaskewingoftheTh1/Th2balancetowardsTh1[17].
2.10.Histopathology. Histopathogenesisofthisdisease,char-
acterized by systemic perivasculitis, with presence of early
neutrophil inﬁltration, endothelial cell swelling, and ﬁbri-
noid necrosis [1–3]. Prominent neutrophil inﬁltration is
seen in all early mucocutaneous lesions. Recurrent aphthous
ulceration, skin pathergy reaction, nodular cutaneous lesion,
and also ocular lesion show this type of histopathologic
pattern [3, 4].
3. Novel Treatment of Behc ¸et’s Diseases
Basedon Immunopathogenesis
In general, BD patients have been treated for suppressing the
symptoms. Conventional therapeutic approaches suppress
the activity of the leucocytes (antiinﬂammatory) and lym-
phocytes (immunosuppressive) in T-cell-mediated diseases,
for the suppression of the immune system. Generally, BD
patients have been treated with the antisymptomatic drugs
as follows; immunosuppressants such as nonsteroid anti-
inﬂammatory agents, steroids, colchicine, cyclosporine-A.
[1, 3, 4]. Meanwhile, the treatment of BD therapy re- mains
still empirical, but nowadays new insights into BD im-
munopathogenesis have led to novel therapeutic approaches
[18–20].Ontheotherhand, HSPseemstoplayanimportant
role in the pathogenesis of BD. The probability of a new
therapy for BD should be as the immune tolerance utilizing
the peptides of HSP.
3.1. Biologic Agents. Clinical and laboratory observations
suggested an important role of TNF-mediated process in
the pathogenesis of BD [21–25]. During the last ten-year
period, 3 licenced TNF antagonists drugs such as inﬂiximab
(chimeric anti-TNF-αmonoclonal antibody), adalimumab
(humanized anti-TNF-αmonoclonal antibody) and etaner-
c e p t( f u s i o np r o t e i nh u m a np 7 5T N F - α receptor IgG1) are
increasingly used oﬀ-label for patients with BD.
Oﬀ-label use of antitumor necrosis factor (TNF) agents
for BD is increasing. It was found 88,12 and 13 primary arti-
clesoninﬂiximab,etanercept,andadalimumab,reportingon
325, 37, and 28 patients, respectively [21]. Increased levels of
TNF, soluble TNF receptors, and TNF-producing cells were
found in the peripheral blood of patients with active disease.
Among inﬂammatory cytokine-related genes, TNF blockade
reduced expression of IL-1 receptor type 2, interferon γ re-
ceptors, IL-6, IL-6 receptors, and IL-17 receptors [22]. It was
found that inﬂiximab is capable of interfering with γδ+T cell
function in BD characterized by dysregulated cell-mediated
immunity [23]. Overall, the majority of patients treated
with either inﬂiximab, etanercept, or adalimumab showed
improvement of their mucocutaneous manifestations [21].
3.2. Anti-TNF Agents
3.2.1. Inﬂiximab. Inﬂiximab most frequently has been used
in BD [24–31]. The dosing regimen for Inﬂiximab was
5mg/kg IV at weeks 0, 2, 6, and every 8 weeks thereafter
[24] and most of these patients were treated with inﬂiximab;
remission of oral ulcers, genital ulcers, erythema nodosum,
and other skin lesions were noticed in 91%, 96%, 81%, and
77% of them, respectively. A rapid and dramatic improve-
ment of visual acuity and decrease of ocular inﬂammation
starting 24 hours after inﬂiximab was reported [24, 25]. And
also long-term eﬀects of repetitive inﬂiximab infusions had
positive results regarding the prevention of ocular relapses
and tapering of immunosuppressive therapy [25]. Inﬂiximab
was used extensively in entero-Behc ¸et, neuro Behc ¸et, and
mucocutaneous BD resistant to conventional therapy [26,4 Pathology Research International
27]. Inﬂiximab showed satisfactory results in patients with
progressive neuro-BD in diﬀerent clinical study [25–27].
Experience with inﬂiximab for vascular involvement is lim-
ited to case reports. But response to this drug was impressive,
with resolution of symptoms within days and improvement
of laboratory and imaging ﬁndings [29]. But in some cases
of BD, TNF blockers are not enough for suppressing the
sympoms of the BD. In one series, the combination of inﬂix-
imabandmethotraxatebringsaboutlong-termalleviationof
entero-BD and excellent tolerability. [31]
3.2.2. Etanercept. Etanercept was administered subcuta-
neously (SC) in a dose of 25mg twice a week or 50mg
once a week. Etanercept was found successful in sustaining
remission for mucocutaneous ﬁndings in signiﬁcantly more
patients than placebo [32–34]. Using the etanercept for ocu-
lar involvement was found in small case series. Etanercept
was found eﬀective in more than half of patients treated with
etanercept [32, 33]. Isolated patients with central nervous
system involvement were treated with etanercept with favor-
able results [32, 34].
3.2.3. Adalimumab. Adalimumab was administered SC as
40mg every 15 days [21]. Using the etanercept and adal-
imumab for ocular involvement was found in small case
series. Complete remission was achieved in all patients
treated with adalimumab. 3 patients with gastrointestinal
involvement havebeen treated successfullywithadalimumab
[34, 35]. On the other hand, few patients with central
nervous system involvement were treated with adalimumab
with good results [36]. In large clinical study, a total of 69
patients with BD have been treated with inﬂiximab. But
seventeen of these (25%) have been switched to adalimumab
for lack or loss of eﬃcacy or infusion reactions. It can be
postulated that patients with BD showing a scarce response
or adverse events to inﬂiximab may successfully be treated
with adalimumab [37].
There is enough published experience to suggest that
TNF blockade represents an important therapeutic advance-
ment for patients with severe and resistant, or intolerant, to
standard immunosuppresive regimens BD.
3.2.4. Rituximab. Rituximab is a chimeric monoclonal anti-
body that acts against the speciﬁc B cell antigen, CD 20.
Rituximab was found eﬀective in retinal vasculitis and ocular
manifestations in BD [38, 39]. Twenty patients of with
intractable ocular lesions of BD were randomized to a ritux-
imab or cytotoxic drugs such as methotraxate, prednisone,
and cyclophosphamide [38]. Rituximab was found eﬀective
in ocular lesions of the diseases [38, 39].
3.2.5. Campath 1-H. Campath 1-h is a humanized anti-
CD52antibody.TheCD52antigenispresentonlymphocytes
and macrophages, but the predominant eﬀect of anti-CD52
antibodytherapy(CAMPATH1-H)isT-celldepletion.Lock-
wood et al. explored the therapeutic response to lymphocyte
depletion with a humanized anti-CD 52 antibody in active
BD. This drug will be a potential alternative treatment for
refractory BD [40].
3.2.6. Toclizumab. Toclizumab is a humanized anti-inter-
leukin 6 receptor antibody. Toclizumab binds both to sol-
uble and to membrane-bound IL-6 receptor [41, 42]. Evi-
dences showed that IL-6 has a crucial role in the neuro-
immunology of neuro-Behc ¸et diseases. Therefore inhibition
of IL-6 signaling could be a new therapeutic regimen for
Neuro-Behc ¸etdiseases[41].Tocolizumabwasusedin47year
old female with recraftory BD. Excellent results were ob-
tainedfor1year.Thisexperienceindicatesthattocol-izumab
may constitute a therapeutic option for refractory BD [42].
3.2.7. Gevokizumab. Gevokizumab (XOMA-052) is an Ig G2
humanized monoclonal antibody against human IL-1β,f o r
the potential treatment of BD. In future, this drug will be
candidate for the treatment of uveitis in patients with the
vasculitic diseases such as BD [43].
3.2.8. Rilonacept and Canakinumab. Two new orphan medi-
cines,Rilonacept(Regeneron)andCanakinumab(Ilaris),are
a human anti-IL-1β monoclonal antibody. Their mode of
action are based on the neutralization of IL-1β signaling,
resulting in supression of inﬂammation in patients with
disorders of autoinﬂammation. [44, 45]. IL-1β is one of
the major cytokines implicated in the pathogenesis of many
inﬂammatory-associated diseases. IL-1β is, therefore, be-
coming a focus for the development of new anti-inﬂam-
matory drug products [44]. Reports from clinical trials sug-
gest that two drugs was were well tolerated in most patients
and no serious adverse efeects were observed [45].
3.3. Tolerization Therapy. Heat shock proteins (HSPs) are
synthesized when cells are exposed to nonspeciﬁc stimuli
such as trauma, heat, and infection HSP has played major
role in pathogenesis of BD. Tolerance induction has been
used for the treatment of autoimmune uveitis [18, 20].
Within HSP-60, the 336–351 sequence has been shown to
induce uveitis when administered subcutaneously. Oral
administrationofthe336–351peptidelinkedtorecombinant
cholera B-toxin B subunit (CTB) was found eﬀective in in-
hibiting the development of uveitis. There were not ob-
served adverse eﬀects during the therapy. Tolerization could
becomeanappealingtherapeuticoptionbecauseofitslackof
side eﬀects and the possibility of the use of other treatment
modalities [19, 20].
3.4. Immunoablation. Immunoablation with autologous
hematopoieticcelltransplantationhasshownsomeeﬀective-
ness in the treatment of autoimmune diseases. Myeloablative
chemotherapy with immunosuppressive drugs followed by
autologous transplantation of T-cell-depleted hematopoietic
stemcellswasfoundtobesafeandeﬀectiveinBD[18].Espe-
cially in some cases resistant to immunosuppressive drugs,
immunoablations could be alternative treatment modalities
to control to BD [20].Pathology Research International 5
3.5. Other Drugs
3.5.1. Rebamipide. Rebamipide can be used for oral aphtous
ulcers in BD. This drug inhibits free radicals derived from
activated neutrophils and decreases the inhibiting inﬂamma-
tory cytokine [45, 46]. Matsuda et al. used the rebamipide
in a multicenter, double-blind, placebo-controlled study 35
patients with BD were randomized 300mg/day or placebo
for 12–24 weeks. In this study, rebamipide was well tolerated
and signiﬁcantly improved the recurrent aphtous stomatitis
[46]. In a recent study, Bang et al. used rebamipide plus
colchicine versus colchicine in the treatment to BD-like
mice. They found that rebamipide helped the function of
colchicine to improve the Herpes simplex virus-induced BD
symptomsbyinhibitingtheexpressionofNADPHoxidasein
av i v om o u s em o d e l[ 47].
3.5.2.Immunomodulators. Tacrolimusandpimecrolimusare
macrolide antiinﬂammatory drugs with potent immunosup-
pressive activity [48–51]. Tacrolimus is used for its capacity
to inhibit T-cell cytokines, such as IL-2, IL-4, and TNF-α.
Oral and topical tacrolimus were used to treat the intestinal
and ocular BD [47, 48]. On the other hand, in a clinical trial,
topical pimecrolimus cream plus colchicine tablets versus
colchicine tablets were used in the treatment of genital ulcers
in BD. Pimecrolimus cream shortens the pain duration in
genital ulcers [50]. In another clinical study, pimecrolimus
versus placebo was used in genital ulcer of BD and also
pimecrolimus was found safe and eﬃcient in the treatment
of genital ulcers, by accelerating the healing [51].
3.5.3. Mycophenolate Sodium. Mycophenolic acid (MPA)
is a potent, selective, and reversible inhibitor of ino-
sine monophospate dehydrogenase and adenosine deam-
inase. Enteric-coated mycophenolate sodium (EC-MPS),
monosodium salt of MPA, allows delayed release of MPA
into the small intestine, and it is associated with less adverse
eﬀects [52]. Ten patients received enteric-coated formulation
of mycophenolate sodium in a standard dose of 720mg
twice daily for six months. Treatment with EC-MPS leads to
signiﬁcant decrease in BD activity. Side eﬀects were mild and
did not lead to discontinuation of therapy [53].
3.5.4. Mycophenolate Mofetil. It was presented that 4 cases
withparenchymalneuro-BD,whereusedimmunosuppresive
drugs could not be continued to intolerance or ineﬃcacy.
These patients beneﬁted well from mycophenolate mofetil.
The beneﬁt was sustained during 3–7 years of follow-up
[54].
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